Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure

The advent of disease modifying therapies (DMT) in the past two decades has been the cornerstone of successful clinical management of multiple sclerosis (MS). Despite the great strides made in reducing the relapse frequency and occurrence of new signal changes on neuroimaging in patients with relaps...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Navid Manouchehri, Victor H. Salinas, Negar Rabi Yeganeh, David Pitt, Rehana Z. Hussain, Olaf Stuve
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-03-01
Saila:	Frontiers in Neurology
Gaiak:	adaptive immunity innate immunity multiple sclerosis immunosenescence progressive multiple sclerosis disease modifying therapies
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fneur.2022.854390/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!